drugset / Trial / NCT04026958
Clarithromycin Mechanisms in Hypersomnia Syndromes
Phase 2
Completed
83 enrolled
Emory University
National Institute of Neurological Disorders and Stroke (NINDS) · collab
RandomizedParallel-groupDouble-blindBasic science
Summary
The purpose of this study is to evaluate a medication called clarithromycin for treating sleepiness in narcolepsy and idiopathic hypersomnia. Studies have shown that clarithromycin can reduce sleepiness, but researchers do not know how clarithromycin does this. This study will look at brain activity (on magnetic resonance imaging \[MRI\]), inflammation, bacteria living in the gut, and cerebrospinal fluid, to better understand how clarithromycin can reduce sleepiness. This study will recruit 92 participants who will be randomized to receive clarithromycin or a placebo for 14 days.
Timeline
- Start
- 2019-09-04
- Primary completion
- 2025-06-18
- Completion
- 2025-06-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Clarithromycin | Small molecule | 500 mg | — |